Interestingly, in our studies a STAT1 inhibitor restored the sensitivity of RANK-overexpressing BC cells to CDK4/6i, highlighting the role of the STAT1 axis in RANK-mediated resistance to CDK4/6i. Here, CDK4 is linked to breast cancer.